A bismuth-peptide complex in the treatment of duodenal ulceration. A double-blind duodenoscopic study.
A bismuth-protein complex (Bicitropeptide, BCP-Compound) active at an acid pH was studied in a trial of treatment in ambulant patients with duodenal ulcers. BCP is said to have an affinity for actively granulating tissue, and to coat the ulcer with a protective layer, allowing healing to occur. A double-blind trial of BCP and placebo was undertaken in 60 patients with duodenal ulcers. Assessments were made by duodenoscopy. Healing of the ulcers occurred in 89% of patients on BCP, and the mean time for the disappearance of symptoms on BCP was 4,9 days. Only 16% of ulcers healed on placebo, and the mean time for disappearance of symptoms on placebo was 6,8 days. This result is highly significant and in favour of BCP (X-2 equals 30,52 P less than 0,0005). No side-effects were observed.
D000293:Adolescent; D000328:Adult; D001729:Bismuth / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004381:Duodenal Ulcer / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004724:Endoscopy; D005260:Female; D005750:Gastric Juice / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010418:Pentagastrin / Q000494:pharmacology; D010455:Peptides / Q000627:therapeutic use*; D010919:Placebos; D012636:Secretory Rate / Q000187:drug effects; D013268:Stimulation, Chemical; D013997:Time Factors
D010455:Peptides; D010919:Placebos; D010418:Pentagastrin; D001729:Bismuth